1C31 nanoparticles
First Claim
Patent Images
1. Pharmaceutical composition in an aqueous mixture form comprising a peptide with the amino acid sequence KLKL5KLK (SEQ ID NO:
- 1) and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 (SEQ ID NO;
2) wherein the peptide and the oligodeoxynucleotide are present as stable complexes, characterized in thatthe peptide is present at a concentration of at least 100 nmol/mL and the oligodeoxynucleotide is present at a concentration of at least 4 nmol/mL,molar ratio of the peptide to the oligodeoxynucleotide is between 20;
1 and 50;
1,mean particle size of the stable complexes comprising the peptide and the oligodeoxynucleotide is less than 1 μ
m,sodium ion concentration is from 0 to 25 mM,the composition optionally comprises Ca2+ ions, phosphate ions, citrate ions, or acetate ions at a concentration of less than 1 mM each,the composition comprises 3 to 10 mM of Tris (Tris(hydroxymethyl)aminomethane) buffer with a pH of 6 to 7.2, 3 to 20 mM of Histidine buffer with a pH of 6 to 7, or 5 to 10 mM of ammonium bicarbonate buffer with a pH of 7 to 8,optionally, the composition has a viscosity less than 15 cP, andoptionally, the composition is sterile.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention discloses pharmaceutical compositions in liquid form comprising a peptide with the amino acid sequence KLKL5KLK and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 and wherein the peptide and the oligodeoxynucleotide are present as sterile-filterable nanoparticles in the composition, thereby forming a suspension, characterized in that the mean particle size of the solid particles is less than 1 μm.
14 Citations
10 Claims
-
1. Pharmaceutical composition in an aqueous mixture form comprising a peptide with the amino acid sequence KLKL5KLK (SEQ ID NO:
- 1) and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 (SEQ ID NO;
2) wherein the peptide and the oligodeoxynucleotide are present as stable complexes, characterized in thatthe peptide is present at a concentration of at least 100 nmol/mL and the oligodeoxynucleotide is present at a concentration of at least 4 nmol/mL, molar ratio of the peptide to the oligodeoxynucleotide is between 20;
1 and 50;
1,mean particle size of the stable complexes comprising the peptide and the oligodeoxynucleotide is less than 1 μ
m,sodium ion concentration is from 0 to 25 mM, the composition optionally comprises Ca2+ ions, phosphate ions, citrate ions, or acetate ions at a concentration of less than 1 mM each, the composition comprises 3 to 10 mM of Tris (Tris(hydroxymethyl)aminomethane) buffer with a pH of 6 to 7.2, 3 to 20 mM of Histidine buffer with a pH of 6 to 7, or 5 to 10 mM of ammonium bicarbonate buffer with a pH of 7 to 8, optionally, the composition has a viscosity less than 15 cP, and optionally, the composition is sterile. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- 1) and an oligodeoxynucleotide with the nucleic acid sequence (dIdC)13 (SEQ ID NO;
Specification